Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

It’s been a year of big stories about Big Pharmas in the healthcare marketing world. | It’s been a year of big stories about ...

Viatris disclosed that its manufacturing facility in Indore, India, was issued a warning letter from the FDA, which banned 11 ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

Lexicon Pharmaceuticals has already thrown in the towel on its commercial efforts after a years-long uphill battle to get its ...

CDMO giant Lonza unveiled plans to expand hard gelatin capsule production capacity at plants in India and China a week after ...

Current treatments for chronic hand eczema (CHE) generally fall into two buckets: Either they battle inflammation but lead to ...

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...

Christmas seems to have come early for Klick Health, with a slew of new leaders arriving under the life sciences marketing ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...